Status:

UNKNOWN

Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease

Lead Sponsor:

Hospital Universitario Dr. Jose E. Gonzalez

Conditions:

Chronic Graft-versus-host-disease

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Chronic graft-versus-host disease (cGVHD) affects 30 to 70% of Allogeneic Hematopoietic Cell Transplantation, decreases the quality of life, and increases mortality. First-line treatments for cGVHD ar...

Detailed Description

In this phase 2 clinical trial, patients with newly diagnosed cGVHD and refractory cGVHD will receive low-dose ibrutinib (140mg/day) combined with a cytochrome 3A4 inhibitor (itraconazole, 100mg BID) ...

Eligibility Criteria

Inclusion

  • Age (\>18 years)
  • Any type of peripheral blood stem cell transplant (matched-related, match non-related, and haplo)
  • Any conditioning regimen
  • Newly diagnosed moderate to severe chronic graft versus host disease
  • Steroid refractory moderate to severe chronic graft versus host disease defined as progression with prednisone 1mg/kg/day, or stable disease after four to six weeks of prednisone \>0.5 mg/kg/day, or disease progression when reducing prednisone below \<0.5 mg/kg/día.
  • 5\. Eastern Cooperative Oncology Group (ECOG) \<= 2

Exclusion

  • Disease relapse (excluding positive minimal residual disease)
  • Secondary malignancies
  • Disease progression
  • Use of B lymphocyte cytotoxics in the last month (i.e., rituximab, bortezomib)
  • Advance stages of heart failure (NYHA III o IV)
  • Ventricular arrhythmias
  • Uncontrolled hypertension
  • Ischemic heart diseases such as unstable angina or stable angina in the last six months
  • Hepatitis B or C
  • Hypersensitivity to ibrutinib
  • Active bleeding
  • Uncontrolled acute infection
  • Hepatopathy Child-Pugh C
  • Pregnancy

Key Trial Info

Start Date :

April 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2023

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT05348096

Start Date

April 1 2022

End Date

August 1 2023

Last Update

April 27 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Universitario Dr. José Eleuterio González

Monterrey, Nuevo León, Mexico, 64630